TiGenix Lead Compound Cx601 Efficient in Treating CD Patients’ Perianal Fistulas
Crohn's Disease, News
TiGenix, a leading biopharmaceutical company developing therapeutics based on adult stem cells, recently announced the results of the Phase III ADMIRE-CD clinical trial, testing the company’s lead compound Cx601 on Crohn’s disease ... Read more